FI3676297T3 - Yhdisteitä, koostumuksia ja menetelmiä - Google Patents
Yhdisteitä, koostumuksia ja menetelmiä Download PDFInfo
- Publication number
- FI3676297T3 FI3676297T3 FIEP18850713.1T FI18850713T FI3676297T3 FI 3676297 T3 FI3676297 T3 FI 3676297T3 FI 18850713 T FI18850713 T FI 18850713T FI 3676297 T3 FI3676297 T3 FI 3676297T3
- Authority
- FI
- Finland
- Prior art keywords
- tai
- ocf
- tauti
- valinnaisesti
- substituoitu
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 150000001875 compounds Chemical class 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 206010012289 Dementia Diseases 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 241000287828 Gallus gallus Species 0.000 claims 2
- 229930189345 Parkinsonin Natural products 0.000 claims 2
- 241001130469 Tila Species 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 108020004021 3-ketosteroid receptors Proteins 0.000 claims 1
- 102100022440 Battenin Human genes 0.000 claims 1
- 101710199232 Battenin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 claims 1
- 241001000594 Tanna Species 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553750P | 2017-09-01 | 2017-09-01 | |
| US201762609267P | 2017-12-21 | 2017-12-21 | |
| US201862634721P | 2018-02-23 | 2018-02-23 | |
| US201862697281P | 2018-07-12 | 2018-07-12 | |
| PCT/US2018/049197 WO2019046779A1 (en) | 2017-09-01 | 2018-08-31 | COMPOUNDS, COMPOSITIONS AND METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3676297T3 true FI3676297T3 (fi) | 2023-08-08 |
Family
ID=65526108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18850713.1T FI3676297T3 (fi) | 2017-09-01 | 2018-08-31 | Yhdisteitä, koostumuksia ja menetelmiä |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12139478B2 (enExample) |
| EP (2) | EP3676297B1 (enExample) |
| JP (3) | JP7382308B2 (enExample) |
| CN (1) | CN111201245B (enExample) |
| CA (1) | CA3072057A1 (enExample) |
| DK (1) | DK3676297T3 (enExample) |
| ES (1) | ES2952994T3 (enExample) |
| FI (1) | FI3676297T3 (enExample) |
| HU (1) | HUE062446T2 (enExample) |
| MA (1) | MA50063A (enExample) |
| PL (1) | PL3676297T3 (enExample) |
| PT (1) | PT3676297T (enExample) |
| SI (1) | SI3676297T1 (enExample) |
| TW (1) | TW201920129A (enExample) |
| WO (1) | WO2019046779A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111094233B (zh) | 2017-08-09 | 2024-03-15 | 戴纳立制药公司 | 化合物、组合物及方法 |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| RU2020122711A (ru) | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| AU2020261234A1 (en) * | 2019-04-23 | 2021-11-11 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EA202192900A1 (ru) * | 2019-04-23 | 2022-03-18 | Эвотек Интернешнл Гмбх | Модуляторы пути интегрированной реакции на стресс |
| PH12021552759A1 (en) * | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| KR20220133252A (ko) | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| JP2023517944A (ja) * | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| US20230391763A1 (en) * | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| AU2021366303A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CN116761803A (zh) * | 2020-10-22 | 2023-09-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| EP4237413A1 (en) * | 2020-10-30 | 2023-09-06 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| CN116768877A (zh) * | 2022-05-30 | 2023-09-19 | 中国药科大学 | Isr抑制剂及其制备方法和应用 |
| TW202440081A (zh) * | 2023-03-14 | 2024-10-16 | 美商人福醫藥美國公司 | σ-1受體拮抗劑及其應用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585572B3 (fr) | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| CN1198613C (zh) | 1998-10-16 | 2005-04-27 | 第一三得利制药株式会社 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| WO2001081317A1 (en) | 2000-04-26 | 2001-11-01 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| AU2002338334B8 (en) | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2006028904A1 (en) | 2004-09-02 | 2006-03-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| JP4887297B2 (ja) * | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
| JP2008542249A (ja) * | 2005-05-24 | 2008-11-27 | アストラゼネカ アクチボラグ | 抗細菌活性を持つアミノピペリジンキノリン及びそのアザ等立体類似体 |
| CN101336229B (zh) | 2005-12-23 | 2012-06-13 | 西兰岛药物有限公司 | 改性的拟赖氨酸化合物 |
| US20080221100A1 (en) | 2006-10-20 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| EP2167494B1 (en) | 2007-06-15 | 2011-08-17 | Actelion Pharmaceuticals Ltd. | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives |
| CN102232078B (zh) * | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
| CA2763589A1 (en) | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| AU2010262905B2 (en) | 2009-06-17 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| EP2678336B1 (en) | 2011-02-24 | 2016-04-20 | Nerviano Medical Sciences S.r.l. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| KR101779644B1 (ko) | 2011-03-10 | 2017-09-18 | 다이이찌 산쿄 가부시키가이샤 | 디스피로피롤리딘 유도체 |
| PE20140502A1 (es) | 2011-04-22 | 2014-05-02 | Signal Pharm Llc | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas |
| WO2013058448A1 (ko) | 2011-10-20 | 2013-04-25 | 한국해양연구원 | 내분비계 장애물질 노출에 대응하는 바다송사리 유전자 및 이를 이용한 수생태계 환경오염 진단 방법 |
| BR112014019622B8 (pt) | 2012-02-14 | 2020-05-26 | Syngenta Participations Ag | composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas |
| HK1209115A1 (en) | 2012-10-02 | 2016-03-24 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazole derivative |
| JP6506248B2 (ja) | 2013-03-14 | 2019-04-24 | ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー | 二環式鎮痛化合物 |
| AU2014233520B2 (en) | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2015038778A1 (en) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| EP3489232A3 (en) | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| KR20170048588A (ko) | 2014-09-17 | 2017-05-08 | 카리라 파마슈티컬스, 아이앤씨. | 바이사이클릭 화합물 |
| WO2016059453A1 (en) | 2014-10-16 | 2016-04-21 | Fundacion Fraunhofer Chile Research | Biomarkers and therapeutic targets for alzheimer's disease |
| EP3221306B1 (en) | 2014-11-20 | 2019-11-13 | Merck Patent GmbH | Heteroaryl compounds as irak inhibitors and uses thereof |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| PE20180355A1 (es) | 2015-02-25 | 2018-02-21 | Univ Rice William M | Desacetoxitubulisina h y analogos de esta |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CU20170139A7 (es) | 2015-05-05 | 2018-03-13 | Bayer Pharma AG | Derivados de ciclohexano sustituido con amido |
| TW201718557A (zh) * | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| WO2017103851A1 (en) | 2015-12-17 | 2017-06-22 | Astex Therapeutics Limited | Quinoline-3-carboxamides as h-pgds inhibitors |
| TW202506629A (zh) | 2016-05-05 | 2025-02-16 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CN109563071B (zh) | 2016-06-08 | 2021-08-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4途径抑制剂的化学化合物 |
| RU2018146946A (ru) | 2016-06-08 | 2020-07-10 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения |
| JP7006960B2 (ja) | 2016-07-06 | 2022-01-24 | アクイスト エルエルシー | 尿酸量を低下するための化合物およびこれらの使用 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| WO2018107072A1 (en) | 2016-12-08 | 2018-06-14 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| US20200140383A1 (en) | 2017-07-03 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| US20210145771A1 (en) | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN111094233B (zh) | 2017-08-09 | 2024-03-15 | 戴纳立制药公司 | 化合物、组合物及方法 |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| WO2019054430A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018360847B2 (en) | 2017-11-02 | 2023-07-27 | Abbvie Inc. | Modulators of the integrated stress pathway |
| US20200347033A1 (en) | 2017-11-02 | 2020-11-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP7307057B2 (ja) | 2017-11-02 | 2023-07-11 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| KR20200092332A (ko) | 2017-11-02 | 2020-08-03 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절제 |
| RU2020122711A (ru) | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| US20210130308A1 (en) | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| JP2021529814A (ja) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AU2020261234A1 (en) | 2019-04-23 | 2021-11-11 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| PH12021552759A1 (en) | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| AU2020266592A1 (en) | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cyclolakyls as modulators of the integrated stress pathway |
| KR20220133252A (ko) | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| CA3205231A1 (en) | 2020-12-18 | 2022-06-23 | Denali Therapeutics Inc. | Solid forms of a compound |
| US20250376432A1 (en) | 2022-06-23 | 2025-12-11 | Denali Therapeutics Inc. | Process for preparing modulators of eukaryotic initiation factor 2b |
-
2018
- 2018-08-31 PT PT188507131T patent/PT3676297T/pt unknown
- 2018-08-31 DK DK18850713.1T patent/DK3676297T3/da active
- 2018-08-31 TW TW107130678A patent/TW201920129A/zh unknown
- 2018-08-31 PL PL18850713.1T patent/PL3676297T3/pl unknown
- 2018-08-31 ES ES18850713T patent/ES2952994T3/es active Active
- 2018-08-31 US US16/643,168 patent/US12139478B2/en active Active
- 2018-08-31 EP EP18850713.1A patent/EP3676297B1/en active Active
- 2018-08-31 MA MA050063A patent/MA50063A/fr unknown
- 2018-08-31 CA CA3072057A patent/CA3072057A1/en active Pending
- 2018-08-31 FI FIEP18850713.1T patent/FI3676297T3/fi active
- 2018-08-31 JP JP2020511347A patent/JP7382308B2/ja active Active
- 2018-08-31 CN CN201880063335.4A patent/CN111201245B/zh active Active
- 2018-08-31 WO PCT/US2018/049197 patent/WO2019046779A1/en not_active Ceased
- 2018-08-31 EP EP23173466.6A patent/EP4248965A3/en active Pending
- 2018-08-31 HU HUE18850713A patent/HUE062446T2/hu unknown
- 2018-08-31 SI SI201830964T patent/SI3676297T1/sl unknown
-
2023
- 2023-02-28 JP JP2023030214A patent/JP2023060020A/ja active Pending
-
2024
- 2024-04-08 JP JP2024062313A patent/JP2024086819A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200331900A1 (en) | 2020-10-22 |
| MA50063A (fr) | 2021-04-28 |
| PT3676297T (pt) | 2023-08-29 |
| TW201920129A (zh) | 2019-06-01 |
| EP3676297A1 (en) | 2020-07-08 |
| PL3676297T3 (pl) | 2023-12-11 |
| CA3072057A1 (en) | 2019-03-07 |
| JP7382308B2 (ja) | 2023-11-16 |
| EP3676297B1 (en) | 2023-05-17 |
| EP4248965A2 (en) | 2023-09-27 |
| HUE062446T2 (hu) | 2023-11-28 |
| SI3676297T1 (sl) | 2023-12-29 |
| CN111201245A (zh) | 2020-05-26 |
| JP2023060020A (ja) | 2023-04-27 |
| JP2020532506A (ja) | 2020-11-12 |
| US12139478B2 (en) | 2024-11-12 |
| DK3676297T3 (da) | 2023-08-14 |
| EP4248965A3 (en) | 2023-11-22 |
| CN111201245B (zh) | 2024-04-05 |
| ES2952994T3 (es) | 2023-11-07 |
| JP2024086819A (ja) | 2024-06-28 |
| EP3676297A4 (en) | 2021-04-28 |
| WO2019046779A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3676297T3 (fi) | Yhdisteitä, koostumuksia ja menetelmiä | |
| FI4081305T3 (fi) | Diasyyliglyserolikinaasia moduloivia yhdisteitä | |
| ATE454395T1 (de) | Oestrogenderivate als steroid sulphatase inhibitoren | |
| MX2018016347A (es) | Composiciones reticulables de revestimiento formuladas con iniciador latente de carbamato. | |
| MX2009013800A (es) | Derivados de ftalazinona como inhibidores de parp-1. | |
| TW348999B (en) | Dihalopropene compounds, insecticidal/acaricidal agents containing same, and intermediates for their production | |
| MY201121A (en) | Olefin polymerization catalyst comprising cyclotriveratrylene and derivatives thereof | |
| AR104209A1 (es) | Formulación y contenedores de aerosol, inhaladores y similares que contienen la formulación | |
| CL2011000784A1 (es) | Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales. | |
| MX2022008558A (es) | Composiciones herbicidas que incluyen agentes retardantes de la deriva y metodos de preparacion de las mismas. | |
| CA1104056A (en) | Fungicides | |
| EA200000910A1 (ru) | Азабициклические лиганды рецепторов 5нт1 | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| EP3731257A3 (en) | Scanning electron microscope | |
| CN105218949A (zh) | 一种注塑加工用环保聚丙烯 | |
| GB2554306A (en) | A coupler | |
| WO2024189079A3 (en) | High melt strength polypropylene | |
| MX2023002188A (es) | Granulo de detergente. | |
| PT1043316E (pt) | Derivados de nitroimidazole como intensificadores de sensibilidade para a quimioterapia e a radioterapia | |
| PA8504601A1 (es) | Procedimiento para la preparación de compuestos de pirazolo [4,3-d] pirimidin-7-onas-3-piridilsulfonilo e intermedios de los mismo. | |
| EA200200162A1 (ru) | Способ деацилирования липодепсипептидов | |
| Lee et al. | The Displacement Minimization of the tool Center Point by the Crossrail Structure Improvement of the Portal Machine | |
| Bojanic | The Notion and Features of the Region as an Administrative-Political Unit-Norm and Reality | |
| Merewether | Design of shielded cables using saturable ferromagnetic materials | |
| MX2024005890A (es) | Compuestos heteroaromaticos biciclicos y su uso como agentes de control de plagas. |